HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MEDI-547

consists of auristatin linked to an anti-EphA2 monoclonal antibody; has antineoplastic activity

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Coleman, Robert L: 2 articles (02/2013 - 05/2010)
2.	Annunziata, Christina M: 1 article (02/2013)
3.	Buzoianu, Manuela: 1 article (02/2013)
4.	Houston, Nicole D: 1 article (02/2013)
5.	Kohn, Elise C: 1 article (02/2013)
6.	Lechleider, Robert: 1 article (02/2013)
7.	LoRusso, Patricia: 1 article (02/2013)
8.	Robbie, Gabriel: 1 article (02/2013)
9.	Gooya, John: 1 article (05/2010)
10.	Han, Hee-Dong: 1 article (05/2010)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2013 - "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors." 02/01/2013 - "No accumulation of MEDI-547 was observed at 0.08 mg/kg upon administration of a second dose 3 weeks following dose 1. The safety profile of MEDI-547 does not support further clinical investigation in patients with advanced solid tumors." 02/01/2013 - "We aimed to evaluate the safety profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to standard therapy. "
2.	Endometrial Neoplasms (Endometrial Cancer) 05/01/2010 - "The preclinical data for endometrial cancer treatment using MEDI-547 show substantial antitumor activity."

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Monoclonal Antibodies
3.	auristatin

Related Therapies and Procedures

1.	Therapeutics